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ABSTRACT
Background: Previous studies have shown high prevalence of HCV infection among people
living with HIV infection. Coinfected people are at risk of developing liver diseases resulting an
increase rate of mortality. Several risk factors for HIV/HCV coinfection have previously been
identified with injecting drug users (IDU) as the common route of exposure.
Methods: This was cross -sectional study using HIV and HCV registries maintained by
Nebraska Department of Health and Human Services (NE DHHS) from1997 to 2017. A
descriptive analysis was used to characterize the sample. Chi-squared test and Fisher exact test
were selected to compare the different groups. Univariate and multiple variable logistic
regression model chose for the analytical analysis for association between variables.
Results: Of 3256 persons with HIV, 356 were coinfected with HCV resulting a proportion of
11%. Based on HIV diagnosis, 52% persons were coinfected by HCV after being diagnosed with
HIV while 48% acquired their HCV before becoming infected with HIV. Exposure by IDU
(OR=3.8, 95% CI:2.6-6.7), IDU & Heterosexual contact (OR=3.3, 95% CI:1.8-5.8), MSM &
heterosexual contact (OR=2.7, 95% CI:1.1-6.7), MSM & IDU (OR=4.5, 95% CI:2.7-7.5) and all
three factors MSM & IDU & Heterosexual contact (OR=4.8, 95% CI:2.1-11.1) had higher odds
of HIV/HCV coinfection compare to heterosexual contact alone. MSM alone was not a
statistically significant risk factor for coinfection. The 56 years and above age group had highest
odds of HCV coinfection. Moreover, coinfected persons had 1.87 odds of dying (95% CI: 1.422.45) compared to those with HIV alone.
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BACKGROUND
HIV and HCV infections are major global public health problems with overlapping
modes of transmission and overlapping affected populations (WHO, 2018). Chronic infection
with these viruses is among the greatest challenges facing health care systems in the United
States and worldwide (Hadigan & Kottilil, 2011). Globally, there are an estimated 36.9 million
people living with HIV infection and 1.8 million people were newly infected with HIV during
2017 (UNAIDS, 2018). Hepatitis C prevalence is even higher, with an estimated 115 million
people with chronic infection worldwide (WHO,2018) & (Smith & Sterling, 2007). Looking to
HIV/HCV coinfection, the WHO reported that approximately 2.3 million people living with HIV
are coinfected with hepatitis C virus (HCV) worldwide with 1.3 million of those injecting drugs
(persons who inject drugs; PWID) (WHO, 2018).

Overall, it is estimated that HCV infection affects 2–15% of people living with HIV
worldwide (and up to 90% of those are PWID) and the burden of these co-infections is greatest
in the African and South East Asia Regions (WHO, 2018). The sub-Saharan African region
accounts for the majority of HIV/HCV coinfection worldwide due to the high burdens of HIV in
this location (Platt et al., 2016). A study also found that HIV-infected people are on average six
times more likely than HIV-uninfected people to have HCV infection; furthermore, among
people living with HIV infection, the rates of HCV coinfection are elevated among MSM (6.4%)
and among PWID can be as high as 82·4% Platt et al., 2016) &(Cuomo et al., 2018).

In studies from Western Europe and the USA, HCV infection has been found in 25–30%
of HIV-positive persons overall; 72–95% of injection drug users, 1–12% of MSM and 9–27% of
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heterosexuals (Alter, 2006) and Thomas reported that HCV coinfection occurs in one quarter of
HIV-infected persons in Europe, Australia, and the United States (Thomas, 2008). HCV is the
cause of more than three-quarters of liver-related deaths among people living with HIV infection,
Nowadays, approximately one-quarter of HIV-infected individuals in Europe and the USA have
HCV coinfection (d'Arminio Monforte et al., 2009).
In the U.S, the CDC estimates that one quarter of people living with HIV infection in the
United States are also infected with HCV, a bloodborne virus transmitted through direct contact
with the blood of an infected person (CDC, 2018). But a study using surveillance data from 15
states and two cities in the US which collected data from 504 398 persons living with diagnosed
HIV infection at the end of 2014, showed that only 6.7% were coinfected with HCV (Bosh et al.,
2018). The CDC also notes that, in the U.S, HIV/HCV confection is common (50%–90%)
among injection drug users (CDC, 2018).
Many other risk factors and demographic characteristics have been associated with a risk
of HCV coinfection among people living with HIV. These include: being in prison, low
socioeconomic status, the presence of one or more tattoos, a history of trading sex for money or
drugs, having 11 or more sexual partners, and having sex with an intravenous drug user. But in
England, a study showed that the majority acquired HIV and HCV through sex between men
64.9%, followed by injecting drug use; 22.5% and heterosexual contact 12.4% (Ireland et al.,
2018).
Since 2000 there has been recognition in developed countries that there has been a
dramatic rise in the incidence of HCV among people living with HIV, especially in the group of
MSM (Men who have sex with Men) even though sexual transmission of HCV remains
controversial in the general population (Danta & Rodger, 2011). Bollepalli et al., using a
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multivariate regression model, concluded that only intravenous drug use is a significant risk
factor/predictor of HCV/HIV coinfection (Bollepalli et al., 2007).
HIV/HCV Coinfection is associated with high morbidity and mortality, making identification of
these cases crucial as HCV infection progresses more rapidly to liver damage among HIVinfected persons (CDC,2018). Compared to people living with HIV but without HCV, HCV
coinfected patients were more likely to develop cirrhosis, had an increased risk of developing
AIDS, of HIV-related disease and of overall mortality (Andreoni et al., 2012).
Individuals who are coinfected with both viruses are at risk for accelerated liver disease
and consequently cirrhosis, liver failure, and hepatocellular carcinoma with a high rate of
mortality, especially in developing countries (Operskalski & Kovacs, 2011) & (Matthews &
Dore, 2008). Despite tremendous advances in treatment and management of HIV and HCV,
individuals with HIV/HCV coinfection experience a more complicated disease course (Hadigan
& Kottilil, 2011). Complications due to the coinfection are accountable for an approximate 30%
reduction in life expectancy among people who live with these two chronic infections
(Leszczyszyn-Pynka et al., 2018).
In Nebraska, there is a need for current studies examining the burden and risk factors
associated with HCV coinfection among people infected with HIV infection. This study was
undertaken in order to gain an improved understanding of the HIV/HCV coinfection burden in
Nebraska with the expectation that interventions by relevant health authorities could be better
focused and made more efficient in order to prevent and decrease the burden of HCV coinfection
among people infected with the HIV infection.
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In this study we aimed to determine:
1) The prevalence and the sociodemographic characteristics of HCV coinfection among
people living with HIV infection in Nebraska from 1997 to 2017
2) The temporal and spatial distribution of HCV coinfection among people living with
HIV infection in Nebraska from 1997 to 2017
3) The risk factors for HCV coinfection among people living with HIV in Nebraska
from 1997 to 2017

METHODS
Study design and data sources
This was a cross-sectional study using surveillance data from separate HIV/AIDS and
HCV registries. The HIV/AIDS data is stored in the Enhanced HIV/AIDS Reporting System
(eHARS) which is a browser-based, CDC-developed application that assists health departments
with data reporting, data management, and data transfer to CDC.
All Electronic Lab Reports (ELR) are received by the Nebraska Diseases Surveillance
System (NEDSS), which is the web-based disease surveillance system for most reportable
diseases including HCV and HIV. Prior to the NEDSS, the reportable diseases were stored in the
Telecommunications System for Surveillance (NETSS). The HIV lab reports are then imported
into eHARS using a CDC-developed import process through SAS software.
To obtain the final dataset which contains all HIV patients having positive lab report for
hepatitis C, we merged the three datasets (NETSS, NEDSS and eHARS) and then de-identified
using a unique identifier for everyone represented in the dataset using SAS.
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Approval for the study was obtained from the Institutional Review Board (IRB) at the
University of Nebraska Medical Center and all patient data was de-identified to avoid any risk to
patient confidentiality.

Eligibility criteria
The merging process of the registries generated a dataset of 5288 patients from 1983 to
2018. This original dataset contains all the newly diagnosed patients with HIV/AIDS and 424
were coinfected with HCV.
After, applying the following selection criteria:
•

People newly diagnosed with HIV infection between 1997 to 2017. The implementation
of highly active antiretroviral therapy (HAART) in 1996 dramatically altered the life
expectancy, and potentially the behavior, of HIV-infected individuals. Patients with much
longer expectancies have more time and opportunities to acquire additional infections
such as HCV infection. We thus chose to limit our study to the HAART era

•

Reported and enrolled as person living with HIV/AIDS in Nebraska at DHHS registries.

•

Person HIV infected, tested for hepatitis C and the result reported to the NE-DHHS

The final dataset contains 3236 people living with HIV and 356 coinfected with HCV

Modeling and Statistical analysis
This study is divided in three parts as following:
•

A descriptive analysis was conducted in order to summarize the characteristics of the
study sample, including sociodemographic characteristics and effects of HCV coinfection
among people living with HIV. This was accomplished by comparing the different
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proportions (percentage) of people living with HIV infection and those with the
coinfection HIV/HCV. Frequencies were generated to compare the different groups.
•

Our study focused on describing the characteristics of those with the coinfection
HIV/HCV and identified risk factors associated with HCV coinfection among HIV
infected patients. Univariate and multiple logistic regression analyses were conducted in
order to assess the influence of these risk factors.

•

Finally, a descriptive analysis was conducted in order to compare people diagnosed as
having HCV before HIV with those who acquired HCV after receiving an HIV diagnosis.

All variables were transformed to categorical variables and patients were stratified in specific
groups to reduce interaction and confounding effects. Fisher’s exact test was used for the
descriptive analysis. The Interaction among the following variables was checked and all analysis
was conducted using SAS 9.4. The alpha level of 0.05 and confidence interval excluding 1 were
used to determine the statistical significance. ArcGIS was used to determine the geographical
distribution of HIV/HCV coinfected patients within Nebraska.

Variables:
The principle outcome variable in our study was HIV/HCV Coinfection. A person with
HIV/HCV coinfection is defined as someone who has both infections. The main exposures
(transmission categories) were grouped into MSM only, IDU only, Heterosexual contact, MSM
and IDU, MSM & Hetero, IDU and Hetero, MSM & IDU & Hetero, and other (Perinatal, No
Identified Risk, No Reported Risk).
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RESULTS
Of a total 3236 persons reported to the NE-DHHS from 1997 to 2017 as persons living
with HIV/AIDS and 356 people were coinfected with HCV as result, the estimated proportion of
HCV among people living with HIV/AIDS was around 11%.

Figure 1 below represents the percentage per year of HCV coinfection among PLWHA in
Nebraska with an overall increase from 1997 to 2015 and a slight decrease since 2015
16.0
14.0
12.0
10.0
8.0
6.0
4.0
2.0
0.0

Figure 1: Proportion(percentage) of HCV infection among PLWHA in Nebraska, 19972017
Figure 2 and 3 below shows the geographical repartition of HIV infection and HIV/HCV
coinfection in Nebraska during 1997 to 2017. Most of reported cases of HIV/AIDS infection and
HIV/HCV coinfection were in Douglas and Lancaster health districts.
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Figure 2: Distribution of HIV infection only per health district between 1997 to 2017 Nebraska

Figure 3: Distribution of HCV/HIV coinfection per health district between 1997 to 2017, in
Nebraska
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Table 1 describes the characteristics of people living with HIV infection and those living with
HIV/HCV coinfection. The total number of people living with HIV/AIDS (PLWHA) was 3236
and 356 persons were coinfected. Non- Hispanic whites represented over 50% of cases and
non-Hispanic blacks composed around the third of cases. The proportion of Hispanics among
PLWHA was found to be15% vs 8% for HIV/HCV coinfection.
Males accounted for approximately 80% of cases of PLWHA, as well as 80% of
coinfected people. Men who sex with men (MSM) represent 46.5% of PLWHA and only 39 %
for coinfected persons. A heterosexual exposure was found in 15.9% among PLWHA compared
to 9.5% for people coinfected with HCV. The proportion of injection drugs users (IDU) was 3
times higher among people with coinfection HCV compared to those with HIV infection only.
There was no identified risk or reported risk in 24.4% of PLWHA and 18% of coinfected
patients.
When examining by age, approximately 2/3 of cases were between 26 to 45 years, with a
tendency towards older age among people with HIV/HCV coinfection. The percentage of
foreign-born individuals was 28.4% among PLWHA vs 17.3% for those with coinfection. The
stage of HIV infection was similar between the two groups, but the number of deaths was
approximately twice as high (22.7% vs 13.6%) among people with coinfection compared to
those with HIV only.
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Table 1: Descriptive characteristics of people living with HIV/AIDS vs People coinfected with
HCV in Nebraska from 1997 to 2017
Race
White
Black
Hispanic
Asian
Multi-race
Other (AI/AN, NHw/PI)
Gender
Male
Female
Exposure
MSM only
IDU only
Heterosexual only
MSM and IDU
IDU and Hetero
MSM & Hetero
MSM & IDU & Hetero
Other
Age group
Less than 16
17-25
26-35
36-45
46-55
56 and above
Birth Country
USA
Foreign
State of HIV diagnostic
Nebraska
Non-Nebraska
HIV stage
Acute HIV
Clinical Latency
AIDS

HIV only (%)

HIV/HCV (%)

1482(51.4)
798 (27.7)
426(14.7)
62(2.1)
54(1.8)
58(2)

207 (58.1)
96 (26.9)
30 (8.4)
5(1.4)
10(2.8)
8(2.2)

2245(78)
635(22)

268(75.3)
88(24.7)

1339(46.5)
94(3.2)
459(15.9)
130(4.5)
94(3.2)
33(1.1)
27(0.9)
704(24.4)

139(39)
31(8.7)
34(9.5)
44(12.3)
27(7.6)
7(2)
10(2.8)
64(18)

55(1.91)
555(19.2)
1029(35.7)
768(26.6)
374(13)
99(3.4)

1(0.28)
48(13.4)
100(28)
129(36.2)
60(16.8)
18(5)

2058 (71.4)
822(28.5)

295(82.9)
61(17.1)

1844(64)
1036(36)

207(58.1)
149(41.8)

1378(47.8)
1493(51.8)
9(0.31)

158(44.4)
198(55.6)
0(0)
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Vital Status
Alive
2484(86.4)
275(77.2)
Death
391(13.6)
81(22.7)
Total
2880
356
Other/Exposure: (Perinatal, No Identified Risk, No Reported Risk, Sharing Sex Toys, etc.);
other/Race: (Native Hawaiian/Pacific Islander, Native American/Alaska Natives).

Table 2 shows odds ratios associated with different characteristics and risk factors of HIV/HCV
coinfected people. Among the variables considered in the model, using heterosexual contact only
as reference group, MSM had 1.4 times odds of HIV/HCV coinfection but this estimate was not
statistically significant (CI=0.9-2.1). However, IDU, IDU & Hetero, MSM & hetero, MSM &
IDU, MSM & IDU & Hetero had a significant increase in the odds of HIV/HCV coinfection with
respective odds ratios of 3.8, 3.3, 2.7, 4.5 and 4.8. Referring to the 17-26 years age group as a
reference, 36-45 years old (OR=1.7, 95% CI: 1.2-2.5), 46-55 years old (OR=1.7,95% CI: 1.12.6) and 56 years old and above (OR=2.1, 95% CI: 1.1-3.7) had significantly increased odds of
having HIV/HCV coinfection. Based on the birth country and comparing to USA born, foreign
born had 0.7 odds of having HIV/HCV coinfection, this estimated was statistically significant
(OR=0.7, 95% CI=0.4-0.9).
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Table 2: Multivariable analysis results summarizing the odds ratio of HIV/HCV
coinfection
Race
Asian vs White
Black vs White
Hispanic vs White
Multi-race vs White
Other vs White
Exposure category
MSM vs Hetero
IDU vs hetero
IDU & Hetero vs Hetero
MSM & Hetero vs Hetero
MSM & IDU vs Hetero
MSM & IDU & Hetero vs Hetero
Other vs Hetero
Birth sex
Female vs Male
Age group
26-35 vs 17-25
36-45 vs 17-25
46-55 vs 17-25
56-above vs 17-25
Less than 16 vs 17-25
Birth Country
Foreign vs USA
State
Non-Nebraska vs Nebraska

Crude OR

95% Wald CI

1.1
1.2
0.8
1.7
0.8

0.4-3.1
0.9-1.6
0.5-1.27
0.8-3.5
0.3-1.8

1.4
3.8
3.3
2.7
4.5
4.8
1.4

0.9-2.1
2.2-6.7
1.8-5.8
1.1-6.7
2.7-7.5
2.1-11.1
0.9-2.1

1.2

0.9-1.6

1.1
1.7
1.7
2.1
0.2

0.7-1.6
1.2-2.5
1.1-2.6
1.1-3.7
0.0-1.8

0.7

0.4-0.9

1.2

0.9-1.5

Table 3 summarizes the descriptive characteristics of HIV/HCV coinfected people based on the
timing of HIV diagnosis. Of a total 356 coinfected cases, 248 had enough information to enable a
determination as to which infection was diagnosed first. Of those 248 persons, 129 were
diagnosed with HCV after the HIV and 119 were diagnosed with HCV before HIV infection.
The proportion among different races/ethnicities was approximately similar between people
having the HCV before or after HIV infection started. There was not a significant difference in
gender between the two groups. When considering exposure, IDU was twice as prevalent among
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people diagnosed with HCV before HIV compared to those diagnosed with HCV after HIV. The
proportion of people over 46 years old having HCV before HIV was 2 times higher than those
having HCV after HIV infection. The proportion of Non-Nebraskans (moved from another state
to Nebraska) who contracted their HCV infection after HIV was approximately twice that of
those who were infected with HCV first.

Table 3: Descriptive analysis of HIV/HCV coinfection comparing HCV diagnosed after
HIV onset vs HCV diagnosed before HIV
HCV after HIV

HCV before HIV

Race
White
Black
Hispanic
Asian
Multi-race
Other (AI/AN, NHw/PI)

74(57.3)
34(26.3)
10(7.7)
2(1.5)
6(4.6)
3(2.3)

76(63.8)
27(22.7)
11(9.2)
2(1.7)
0(0)
3(2.5)

Gender
Male

98(76)

96(80.7)

Female
Exposure
MSM only

31(24)

23(19.3)

61(47.3)

46(38.6)

IDU only
Heterosexual only
MSM and IDU

7(5.4)
12(9.3)
14(10.8)

12(10.1)
12(10.1)
11(9.2)

IDU and Hetero

9(7)

4(3.3)

MSM & Hetero

1(0.8)

3(2.5)

MSM & IDU & Hetero

4(3.1)

1(0.8)

Other

21(16.3)

30(25.2)

Age group
Less than 16

0(0)

1(0.8)

17-25
26-35
36-45

23(17.8)
42(32.5)
46(35.6)

16(13.4)
31(26)
38(31.9)

46-55

14(10.8)

24(20.2)

56 and above

4(3.1)

9(7.5)

17
Birth Country
USA

105(81.4)

98(82.3)

Foreign
State of HIV diagnostic
Nebraska

24(18.6)

21(17.6)

71(55)

96(80.7)

Non-Nebraska

58(45)

23(19.3)

Total
HIV stage

129

119

Acute HIV

51(39.5)

58(48.7)

Clinical Latency

78(60.5)

61(51.3)

AIDS

0(0)

0(0)

Vital Status
Alive
Death

94(72.9)
35(27.1

93(78.2)
26(21.8)

129

119

Estimated mortality: in a univariate analysis with death as the outcome, coinfected HCV/HIV
had 1.87 odds of dying compare to those with HIV infection only (OR=1.87; 95% CI: 1.422.45).

DISCUSSION
Our study found an estimated proportion of HCV infection among PLWHA of 11%, this
proportion is less than the overall estimate reported by the Centers for Disease Control and
Prevention (2018) of about 25% and less than the 25-30% reported by Alter et al. (2006) in
Europe and the U.S. In contrast, a population-based study using surveillance data from 15 states
in the US and involving 504,398 persons living with diagnosed HIV infection in 2014, revealed
that only 6.7% were coinfected with HCV (Bosh et al., 2018). This study estimated the
proportion of HCV among newly diagnosed HIV infection which may explain the differences
with other studies referring to the prevalence or the incidence rate.
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The incidence of HIV/AIDS infection has declined over the past two decades, but the
prevalence of HCV coinfection increased over the past two decades in Nebraska. This trend was
corroborated by Smith & Sterling (2007) who also reported an increase in acute HCV from
2007 to 2010. According to Hagan et al. (2002) and Edlin, Eckhardt, Holmberg & Swan (2015),
public health surveillance tools may misrepresent the true rates due to under-reporting of cases
of high-risk groups and because better programs of screening may explain the constant
increase in the number of HCV cases reported to health authorities. Since 2015, a decrease of
proportion of notified cases has been seen, but future investigations are needed in order to
understand the real cause of this diminution.
Most cases of HIV/HCV coinfection were reported in the Douglas and Lancaster
County health districts; this is almost certainly due to the number of people in these two
counties, which account for around 50% of persons of all Nebraska according to Nebraska
Department of Health and Human Services (2015).
This study showed that non-Hispanic Whites represented approximately two thirds of
all cases and non-Hispanic Blacks represented approximately one quarter of all cases. In
Nebraska, 80% of people are non-Hispanic white and 4.7% are non-Hispanic Black (Nebraska
Department of Health and Human Services, 2015); therefore, Blacks seem to have a high
incidence than whites in both the PLWHA and HCV coinfection groups). Silverberg, Leyden,
Quesenberry & Horberg (2009) found similar results in a retrospective cohort study of 4,686
HIV-infected patients. Multivariate analysis of our data showed that the odds of having HCV
coinfection was not statistically significantly different when comparing whites to other races.
In England, a study based on national surveillance using Public Health England HIV/AIDS
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database, Blacks had a 3.19-fold increase in the odds of having HIV/HCV coinfection. (Ireland
et al., 2018)
The ratio of males to females was approximately 4:1 among PLWHA and among those
coinfected with HCV. A similar study using surveillance data in New York obtained
approximately the same results males accounting for 70-80% of those living with HCV
coinfection (Prussing et al., 2015). Comparing female and males, the odds of having HCV
coinfection was not statistically significant (OR=1.2; 95% CI 0.9-1.6; see table).
This study showed that most people in Nebraska were infected because they were Men
who have Sex with Men (MSM) and/or Injection Drug Users (IDU). Around 40% of HCV
coinfected individuals acquired their infections through MSM and over 40% were IDU in
addition to other types of exposure. In the multivariate analysis, using heterosexual as reference,
IDU only, IDU & Hetero, MSM & Hetero, MSM & IDU, MSM & IDU & Hetero had significant
odds of having HCV coinfection (Table 3).
MSM had 1.4 times the odds of HIV/HCV coinfection compared to the Hetero group, but
this estimate was not significant (CI=0.9-2.1). Several authors have corroborated these findings,
Bollepalli et al. (2007) found that HCV coinfection was associated with IDU but not with sexual
risk factors and the distribution of sterile needles produced a decline in the prevalence of HIV
among IDU (Burt & Thiede,2016). Another study showed that there was a low prevalence of
HCV coinfection among non-IDU with high-risk sexual behavior, similar to our conclusions
regarding MSM. (Chew et al., 2015). The Centers for Disease Control and Prevention (2011)
reported that 59.9% of hepatitis cases were associated with the use of injection drugs and only
12.9% were associated with sexual exposures.
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There was a difference in the distribution of HIV/AIDS and HCV coinfection among
the different age groups; HIV/AIDS proportion was highest among the 26-35 age groups and
HCV coinfection was highest among the 36-45 age group. HCV coinfected patients tend to be
older compared to the HIV infected only group. After examining the coinfected patients only,
those ages 36-45, 46-55 and 56 and above had positive significant odds of having HIV/HCV
coinfection compared to the 17-25 age group. Furthermore, this study showed that the 56 and
above age group had 2.1 times odds of having HCV coinfection compare to the 17-25 age
group. Most programs are targeting the younger age group (17-25), but this study showed that
older people were more at risk for HCV coinfection may be due to some risk factors/ sexual
risk behaviors and IDU; furthermore, thes persons have lived longer compare to young people
with more opportunities to be exposed.
The proportion of foreign-born individuals is lower among those coinfected with HCV
and multivariate analysis showed that the foreign born had 0.7 times odds of having HCV
coinfection compare to USA born persons with 95% CI= 0.4-0.9. It is known that t foreign
born individuals have higher odds of having HIV infection (table 3), but our study showed that
the risk of HCV coinfection is lower. These results need to be investigated further for
confirmation.
The mortality rate was high among HCV coinfected persons; the current study
concluded that having HCV coinfection increased by 1.87 times the odds of dying compared to
having HIV infection only (OR=1.87; 95% CI: 1.42-2.45). Several studies have published
similar results regarding an increase of the mortality rate among those coinfected with HCV
(Prussing et al., 2015). This high mortality is likely related to liver damage and the acceleration
to AIDS (Andreoni et al., 2012).
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Of a total of 248 persons with HIV/HCV coinfection, 129 persons were infected with
HCV after the HIV started compare to 119 persons who had HCV before the HIV infection. we
could not figure out which group had the higher odds due to the sample size and the type of
study design. Future studies are needed to determine which group is more at risk; these may
help to focus effort for preventing the state of HCV coinfection.

LIMITATIONS AND RECOMMENDATIONS
Missing information and underreporting were on the limitation of this study. Many
persons did not have all their information recorded making challenging the analysis process.
Moreover, this fact decreased the sample size, and the consequence is the loss of power.
Underreporting is a limitation because we could find the exact number of people with HCV
coinfection. Due to the data collection method, we could not capture the real number of people
moved out-Nebraska having coinfection and should be taken into consideration in the reporting
electronic system.
Based on the results of this study, an improved data surveillance of HCV infection,
widespread adoption of electronic health record systems and electronic information exchange
can provide a wealth of new data sources and better monitor the true incidence of HCV infection
among people. High-risk PLWHA should be monitored and targeted for preventive measures to
prevent HCV coinfection. Finally, there is a need for future studies to identify the best public
health interventions to decrease the HCV coinfection among PLWHA in Nebraska.
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CONCLUSION
This study showed that the odds of having HCV coinfection were not statistically
significant based on race. The odds of having HCV coinfection was significant with IDU used
and increased in the case where IDU was associated to another risk sexual behavior, but
surprisingly MSM did not show any increase odds of HCV coinfection compare to the
heterosexual group. Furthermore, it is found that 36 years and above had higher odds of having
HCV compare to 17-25 age group. The mortality was increased among HCV coinfected people.
Future and better study designs are needed to better understand the epidemiology of some
specific groups such as foreign-born. Future and better study designs are required to understand
better some the burden of HCV coinfection among PLWHA in Nebraska.
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